D Blastin Injection 20mg

A qualified oncology team administers it into a rapidly flowing intravenous line, never by intramuscular or subcutaneous injection.

D-Blastin 20mg Injection Ingredients and Usage

D-Blastin 20mg Injection contains daunorubicin, an anthracycline antibiotic belonging to the antitumor antibiotic drug class. Oncologists prescribe it in combination with other approved anticancer drugs for remission induction in acute nonlymphocytic leukemia, including myelogenous, monocytic, and erythroid subtypes, in adults.

D-Blastin 20mg Injection is also used for remission induction in acute lymphocytic leukemia in children and adults. It must only be administered by physicians experienced in leukemia chemotherapy, in a facility equipped to monitor drug tolerance and manage complications.

How Does D-Blastin 20mg Injection Work?

Daunorubicin intercalates between DNA base pairs, forming a stable complex that interferes with nucleic acid synthesis. It also inhibits topoisomerase II, an enzyme cancer cells need to manage DNA structure during replication.

By disrupting DNA function through multiple mechanisms, D-Blastin 20mg Injection blocks cancer cell division and triggers cell death. This same interaction with topoisomerase II in heart muscle cells is the basis for the drug's dose related cardiac toxicity.

D-Blastin 20mg Injection Side Effects

D-Blastin 20mg Injection commonly causes blood count changes and digestive side effects.

• Low white blood cell and platelet counts

• Nausea and vomiting

• Hair loss

• Mouth sores, usually appearing 3 to 7 days after treatment

• Loss of appetite

• Pink or red discoloration of urine for up to 48 hours after the dose

• Diarrhea and abdominal pain

Warnings

• D-Blastin 20mg Injection must be given into a rapidly flowing intravenous line and never by intramuscular or subcutaneous injection; severe tissue necrosis will occur if the drug leaks outside the vein.

• The medicine can cause potentially fatal congestive heart failure, which may appear during treatment or months to years after it ends; cardiac risk rises sharply once the cumulative lifetime dose exceeds 400 to 550 mg per square meter in adults.

• Cardiac monitoring with ECG and echocardiogram is required before starting treatment and periodically throughout, particularly in patients with prior anthracycline exposure or chest radiation.

• Severe myelosuppression occurs at therapeutic doses and can lead to serious infection or hemorrhage; blood counts must be monitored closely.

• Dose reduction is required in patients with impaired liver function, since daunorubicin clearance depends on the liver.

• D-Blastin 20mg Injection is teratogenic; women of childbearing potential should avoid pregnancy during treatment.

• Cardiotoxicity may occur more frequently and at lower cumulative doses in children and elderly patients; dosing requires extra caution in these groups.

D-Blastin 20mg Injection Storage Conditions

Store D-Blastin 20mg Injection as directed on the vial label, protected from light. Keep the vial in its original packaging until immediately before use. Store this medicine out of reach of children and ensure only trained healthcare staff handle preparation and administration.